TY - JOUR
T1 - Omalizumab for Chronic Urticaria:
T2 - Aftermarket Reports of Efficacy and Side Effect
AU - Ghazanfar, Misbah Nasheela
AU - Thomsen, Simon Francis
PY - 2017
Y1 - 2017
N2 - Purpose of Review The purpose of this study was to review
real-life studies on effectiveness and safety of omalizumab in
chronic urticaria (CU).
Recent Findings CU is an itching skin disease characterized
by wheals, angioedema, or both (present >6 weeks).
Omalizumab is a humanized anti-IgE monoclonal antibody
approved for treatment of CU and is becoming one of the main
treatment options for antihistamine-resistant CU; however,
real-life studies on long-term effectiveness and safety are
lacking.
Summary We present an overview of the real-life literature
totaling 505 patients with an age range of 7–82 years, on the
effectiveness and safety of omalizumab used for CU since
2013. A complete response to omalizumab was seen among
64% of the patients, whereas 25% obtained partial response.
On average, 15% had no or very limited response. Fifteen
patients from five studies reported side effects. Overall,
omalizumab was effective and well-tolerated for patients with
antihistamine-resistant CU.
AB - Purpose of Review The purpose of this study was to review
real-life studies on effectiveness and safety of omalizumab in
chronic urticaria (CU).
Recent Findings CU is an itching skin disease characterized
by wheals, angioedema, or both (present >6 weeks).
Omalizumab is a humanized anti-IgE monoclonal antibody
approved for treatment of CU and is becoming one of the main
treatment options for antihistamine-resistant CU; however,
real-life studies on long-term effectiveness and safety are
lacking.
Summary We present an overview of the real-life literature
totaling 505 patients with an age range of 7–82 years, on the
effectiveness and safety of omalizumab used for CU since
2013. A complete response to omalizumab was seen among
64% of the patients, whereas 25% obtained partial response.
On average, 15% had no or very limited response. Fifteen
patients from five studies reported side effects. Overall,
omalizumab was effective and well-tolerated for patients with
antihistamine-resistant CU.
U2 - 10.1007/s13671-017-0182-9
DO - 10.1007/s13671-017-0182-9
M3 - Review
SN - 2162-4933
VL - 6
SP - 48
EP - 54
JO - Current Dermatology Reports
JF - Current Dermatology Reports
ER -